New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation ...

Differentiated thyroid cancer patients who receive radioiodine (RAI) treatment after surgery have increased relative survival rates compared to those who do not receive the treatment.&nbsp ...

Published in the journal Thyroid, the study identifies an epigenetic signature comprising 156 CpG sites in primary tumors that could help stratify patients according to their risk of developing ...

Papillary thyroid cancer is the most common type of thyroid cancer and usually grows slowly. It can remain undetected for a long time.

Stage 4 thyroid cancer is the most serious; stage 1 is the least severe. The stage of someone's cancer is determined by the size and spread of cancer cells from a tumor's primary site, in this case, ...

Lori J. Wirth, MD, discusses some of the unmet needs that exist in the thyroid cancer space following the FDA approval for lenvatinib for radioactive iodine-refractory differentiated thyroid cancer.

A new study has shown that overall and cause-specific mortality rates in individuals in the U.S. with low-risk differentiated thyroid cancer (DTC) are low.

Papillary thyroid cancer is a type of differentiated thyroid cancer, which means it starts in cells that make and release thyroid hormones. It typically forms in only one lobe of the thyroid gland ...

More than one-third of patients treated for differentiated thyroid cancer reported elevated anxiety and more than 15% reported a high level of depression at an annual follow-up, according to study ...

One nice thing about differentiated thyroid cancer is that it usually produces a protein called thyroglobulin. Thyroglobulin in the blood stream indicates the presence of thyroid tissue. If I have a ...

Health care specialists provide an overview on the nature of differentiated thyroid cancer and discuss subtypes of disease that patients may present with.

The FDA has approved Cabometyx (cabozantinib) for the treatment of patients with locally advanced or metastatic differentiated thyroid cancer.